DOJ Alleges $1.6 Billion in Addiction Treatment Fraud. Responsible Providers Have a Stake in What Comes Next.

The allegations raise serious questions about patient protection, treatment decisions, and the integrity of billing. Providers can respond with greater accountability and clearer evidence of appropriate care.

On October 22nd, 2026, the U.S. Department of Justice announced charges in an alleged addiction treatment scheme involving over $1.6 billion billed to private insurers. The case was part of a broader Los Angeles healthcare fraud announcement involving 15 defendants across several schemes.

According to prosecutors, the alleged conduct included recruiting vulnerable people with financial inducements, cycling patients through facilities regardless of medical necessity, and billing for sham treatment. Prosecutors also alleged that patients were coached to fabricate symptoms and sometimes prevented from leaving facilities.

These are allegations, not findings of guilt. The defendants facing charges are presumed innocent unless proven guilty. DOJ separately reported that a participant in the related scheme had pleaded guilty.

The concerns go beyond documentation. They question whether vulnerable people received appropriate care and whether treatment decisions served their interests.

For those of us working in addiction treatment and the organizations that support it, that deserves a serious response.

Patient needs must guide treatment decisions.

People entering addiction treatment may be navigating withdrawal, unstable housing, strained family relationships, or previous treatment experiences that failed to meet their needs. They place considerable trust in those offering help.

That trust creates obligations from admission through continuing care.

Admissions should reflect whether a program can meet a person’s clinical needs. Treatment plans should follow an individual assessment. Decisions about continued care should reflect the patient’s condition and response to treatment.

The DOJ's allegations illustrate the risks when financial incentives displace those responsibilities.

A provider’s financial sustainability matters, as does payment for appropriate services. Neither justifies improper recruitment, services that do not meet a patient’s needs, or treatment continued for reasons unrelated to care.

Responsible providers should be able to explain how their admissions, clinical, and billing practices protect against those risks.

Trust extends beyond any single organization.

An alleged scheme does not establish how an entire industry operates. Responsible addiction treatment providers should not be treated as interchangeable with the organizations described in a criminal case.

Still, allegations like these can undermine broader confidence.

Families may question how to recognize trustworthy treatment. Payers may question whether the records they receive accurately describe the care delivered. Providers doing ethical work have an interest in making the answers visible.

This announcement does not establish that payers have imposed new restrictions across the industry. It does give the treatment community another reason to demonstrate accountability through daily practice.

That means being clear about what a program provides, who delivers care, how treatment decisions are made, and how patients and families can raise concerns.

Make payer requirements part of the operating routine.

Payers have a legitimate role in evaluating coverage and checking whether billed services meet applicable requirements. Providers have a responsibility to advocate for clinically appropriate care.

Those responsibilities can coexist, including when a coverage decision is disputed.

Providers can strengthen that process through a few practical steps:

• Keep requirements current. By assigning someone to review provider bulletins, contract notices, policy updates, and relevant newsletters. Record effective dates and translate changes into staff instructions.
• Track authorization precisely. Maintain a current record of requested and approved services, dates, days or units, review deadlines, and unresolved questions.
• Connect clinical and billing teams. Check that assessments, treatment plans, authorization requests, and claims consistently reflect the services delivered.
• Investigate recurring problems. Review denial reasons and payment discrepancies by payer to distinguish documentation gaps, administrative errors, and coverage disagreements.

Requirements vary by payer, plan, state, and service. Reading an update is only the first step. Someone must determine what changed, who is responsible, and whether the change has reached the people doing the work.

Authorization must be tracked separately from payment. For example, Ambetter of Alabama states that prior authorization does not guarantee payment, which depends on eligibility, covered benefits, provider contracts, and correct coding and billing. Providers should check the requirements governing their services and agreements.

Review the full record across the patient’s care.

Better documentation cannot justify inappropriate treatment or legitimize an undelivered service.

For ethical providers, its purpose is to make the clinical reality clear enough for another professional to understand and assess.

That requires longitudinal review and examining the full set of clinical records across the patient’s course of care, rather than assessing each note in isolation.

The review should connect assessments, treatment plans, progress notes, service records, and transition documentation. Together, those records should explain how the patient’s needs changed, what care was delivered, and why the recommended level of care remained medically necessary.

It should also check whether documentation and required signatures were completed within applicable deadlines, and whether statements across the record are consistent.

A note can appear complete alone but raise questions when read with the rest of the chart. An assessment may describe substantial impairment, but later notes may not explain if it persists. A treatment plan may remain unchanged despite a documented change in condition. Service dates or signatures may not meet requirements.

Those discrepancies deserve review. The response should preserve an accurate account of care with corrections or clarifications made through the proper process.

Consistency does not mean every note should say the same thing. Patients change and different clinicians may observe different things. The record should explain meaningful changes and resolve contradictions without erasing legitimate clinical differences.

ASAM describes regular reassessment throughout treatment, using transition and continued service criteria to determine whether a patient should remain at the current level of care or move to a more or less intensive setting. That clinical reasoning should be visible across the record.

If a patient is improving, document the improvement. If significant risks remain, explain them. If the treatment plan changes, record why. If the patient is ready to transition, document the rationale and next steps.

An honest account of progress and a clear explanation of continuing need can belong in the same chart.

Show how patients are responding to care.

Documentation should help answer a question central to both clinical care and payer discussions: What is changing for the patient?

When appropriate for the patient and setting, standardized measures can help teams track that change over time:

• The Brief Addiction Monitor (BAM) captures substance use and recovery-related factors.
• The PHQ-9 can help track depressive symptoms.
• The GAD-7 can help track anxiety symptoms.

Repeated measures are most useful when clinicians interpret them alongside the broader record and use findings to inform care. A score alone does not establish medical necessity or prove a program caused improvement.

Narrative notes also contain important information: changes in functioning, engagement, cravings, recovery supports, and barriers to transition. Reviewing that information alongside standardized measures can give a fuller account of the patient’s course.

At Circle, we're pursuing this direction: helping teams organize information from narrative records and visualize changes over time. Summaries must remain traceable to their source, preserve uncertainty, and undergo clinical review. Modern systems should help clinicians examine the record without inventing findings or replacing judgment.

For payer discussions, the same discipline matters. Providers should explain what they measured, when, how many patients were included, and where follow-up data is missing. Transparent evidence gives both parties a firmer basis for discussion than broad claims about quality.

Use evidence to advocate for appropriate care and payment.

When a coverage decision appears inconsistent with the patient’s needs or applicable requirements, responsible collaboration includes challenging it through the appropriate review or appeal process.

A strong submission should specify the disagreement. What was requested, why it was clinically appropriate, what evidence supports it, and how that evidence relates to the stated reason for denial.

The aim is to secure authorization for medically necessary care and payment supported by the services delivered, coverage terms, and contract.

Over time, reliable information about care quality, access, outcomes, and operational performance may support reimbursement and rate discussions. It does not guarantee an increase but gives providers a more credible basis for explaining their role in the network and the value they demonstrate.

Put accountability into daily practice.

Circle Health is an affiliate member of the National Association of Addiction Treatment Providers. We support NAATP’s Code of Ethics, including its emphasis on patient rights, appropriate admission and continuing-care criteria, qualified staff, and ongoing evaluation of operations.

Providers can apply those principles by asking:

• Can we explain the clinical rationale for admission, continued treatment, and transition?
• Does the full record accurately describe the patient’s care, with timely documentation and signatures?
• Can clinical, utilization review, and billing teams identify and resolve discrepancies?
• Do patients and families understand how to raise concerns?

Patients and families should be able to seek addiction treatment without questioning whose interests come first.

Responsible providers protect that trust through the decisions they make every day: whom they admit, how they treat, when they recommend a transition, and what they bill. Clear documentation makes those decisions visible and gives providers a stronger basis to advocate for necessary care and fair payment.

The industry’s credibility depends on how consistently it meets those responsibilities.